Significats de severe plaque en anglès

Conclusions: Secukinumab shows efficacy for induction and maintenance treatment of moderate-to- severe plaque psoriasis.

Conclusions: Apremilast was effective in the treatment of moderate-to- severe plaque psoriasis over 52 weeks.

Background: Cyclosporin is an effective treatment for severe plaque psoriasis.

Conclusions: Apremilast was effective in moderate to severe plaque psoriasis.

Patients: Adults with moderate to severe plaque psoriasis, with no previous methotrexate or cyclosporine treatment.

A 61-year-old Caucasian male with severe plaque psoriasis without joint involvement was initiated on adalimumab therapy.

Secukinumab showed robust and sustainable efficacy in symptom reduction for moderate-to- severe plaque psoriasis in the Japanese patients.

Both doses of risankizumab were superior to placebo in treating patients with moderate to severe plaque psoriasis.

Ixekizumab, a high-affinity monoclonal antibody that selectively targets IL-17A, is efficacious for moderate to severe plaque psoriasis.

Interpretation: Risankizumab showed significantly greater efficacy than adalimumab in providing skin clearance in patients with moderate-to- severe plaque psoriasis.

Methods: All Danish patients with moderate-to- severe plaque psoriasis treated with biologics are recorded in the nationwide DERMBIO registry.

This Class I topical corticosteroid has shown to be safe and efficacious in moderate to severe plaque psoriasis.

We aimed to compare the efficacy and safety of risankizumab with adalimumab in patients with moderate-to- severe plaque psoriasis.

Enbrel is used to treat moderate to severe plaque psoriasis, while Aranesp is used to treat certain forms of anemia.

Conclusions and relevance: This study provides an assessment of the comparative efficacy among treatments for moderate to severe plaque psoriasis.

We assessed the clinical efficacy and safety of different doses of apremilast in the treatment of patients with moderate to severe plaque psoriasis.